DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients

Information source: University of Regensburg
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Schizophrenia

Intervention: Quetiapine (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: University of Regensburg

Official(s) and/or principal investigator(s):
Goeran Hajak, MD, PhD, Principal Investigator, Affiliation: University of Regensburg


Aim of the study is to assess the effect of quetiapine treatment in neuroleptic naive, first-episode schizophrenic patients on aspects of functional and structural neuroplasticity assessed by means of transcranial magnetic stimulation and voxel-based morphometry. Main outcome measure is a change in gray matter density under quetiapine treatment from baseline to steady-state-treatment after 3 weeks.

Clinical Details

Official title: Quetiapine Induced Neuroplasticity in Schizophrenic Patients: A Combined Transcranial Magnetic Stimulation (TMS) and Voxel-based Morphometry (VBM) Study

Study design: Intervention Model: Single Group Assignment, Masking: Open Label

Primary outcome: Change of structural neuroplasticity (i.e. change in gray matter density) under treatment with quetiapine assessed by voxel-based morphometry.

Secondary outcome:

Change of functional neuroplasticity (i.e. cortical excitability) under quetiapine treatment assessed by paired-pulse TMS

To evaluate the influence of BDNF gene polymorphisms on clinical effects of quetiapine treatment, cortical excitability and brain morphology


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- diagnosis of first episode of schizophrenia according to Diagnostic and Statistical

Manual of Mental Disorders- Fourth Edition (DSM-IV) criteria and no history of neuroleptic medication

- Females and/or males aged 18 to 65 years

- Mild to moderate schizophrenia

Exclusion Criteria:

- Neuroleptic treatment prior to study enrollment

- Pregnancy or lactation

- Any DSM-IV Axis I disorder not defined in the inclusion criteria

- Patients who, in the opinion of the investigator, pose an imminent risk of suicide or

a danger to self or others

- Known intolerance or lack of response to quetiapine fumarate as judged by the


- Use of any of the following cytochrome P450 3A4 inhibitors in the 14 days preceding

enrolment including but not limited to: ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, troleandomycin, indinavir, nelfinavir, ritonavir, fluvoxamine and saquinavir

- Use of any of the following cytochrome P450 inducers in the 14 days preceding

enrolment including but not limited to: phenytoin, carbamazepine, barbiturates, rifampin, St. John's Wort, and glucocorticoids

- Any history of neuroleptic treatment

- Substance or alcohol dependence at enrollment (except dependence in full remission,

and except for caffeine or nicotine dependence), as defined by DSM-IV criteria

- Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse by DSM-IV

criteria within 4 weeks prior to enrollment

- Medical conditions that would affect absorption, distribution, metabolism, or

excretion of study treatment

- Unstable or inadequately treated medical illness (e. g. angina pectoris, hypertension,

congestive heart failure) as judged by the investigator

- Involvement in the planning and conduct of the study

- History of or evidence of significant brain malformation or neoplasm, head injury,

cerebral vascular events, neurodegenerative disorder affecting the brain or prior brain surgery

- Concomitant treatment with psychotropic drugs (e. g. antidepressive agents,

anticonvulsants, other neuroleptics) except benzodiazepines or hypnotics

Locations and Contacts

University of Regensburg, Department of Psychiatry, Regensburg 93053, Germany
Additional Information

Starting date: March 2008
Last updated: October 21, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017